BioCentury | Apr 4, 2020
Finance

Megarounds for Chinese biopharmas Legend, RemeGen to support late-stage push

A pair of Chinese biotechs raised rounds topping $100 million this week, with Legend’s fund-raise coming ahead of a planned U.S. IPO and regulatory submissions for its lead CAR T targeting BCMA, and cancer and...
BioCentury | Jun 18, 2012
Product Development

Immune springboard

A spate of Phase III data events over the next two years will give a readout on how correctly the lessons learned five years ago about cancer immunotherapies targeting T cell responses have been put...
BC Week In Review | Dec 19, 2011
Company News

Ritter management update

Ritter Pharmaceuticals Inc. , Los Angeles. Calif.   Business: Gastrointestinal   Hired: Robert Tidwell as CBO, formerly SVP of corporate development at Cell Genesys Inc. , which merged with BioSante Pharmaceuticals Inc.  ...
BC Week In Review | Nov 7, 2011
Company News

Pathwork Diagnostics management update

Pathwork Diagnostics Inc. , Redwood City, Calif.   Business: Diagnostic   Hired: Sharon Tetlow as CFO, formerly SVP and CFO of Cell Genesys Inc. , which merged with BioSante Pharmaceuticals Inc.  ...
BC Week In Review | Jun 13, 2011
Clinical News

GVAX Prostate cancer vaccine: Development restarted

BioSante said FDA lifted a clinical hold on the GVAX Prostate cancer vaccine to treat prostate cancer after additional data analyses addressed side effect concerns. BioSante is planning to begin a Phase II trial of...
BC Extra | Jun 7, 2011
Clinical News

FDA lifts hold on BioSante vaccine

FDA lifted a clinical hold on GVAX Prostate Cancer vaccine from BioSante Pharmaceuticals Inc. (NASDAQ:BPAX). The company said the hold was lifted after additional data analyses addressed side-effect concerns. BioSante is planning to begin a...
BioCentury | May 23, 2011
Strategy

Takeda's global boost

Acquiring Nycomed will transform Takeda Pharmaceutical Co. Ltd. into a complete global pharma company by combining geographically complementary marketing operations. But the Japanese pharma will need more acquisitions to get its market cap back to...
BC Week In Review | Nov 22, 2010
Company News

BioSante, Cold Genesys deal

Cold Genesys received exclusive, worldwide rights to develop and commercialize BioSante's oncolytic virus technology, including CG0070 . BioSante received a 19.9% ownership of Cold Genesys, a $95,000 upfront payment and is eligible to receive milestones and...
BC Innovations | May 27, 2010
Targets & Mechanisms

Coaxing cancer to defect

The immune system has a hard time attacking tumors because malignant cells do not express potent antigens that could elicit a strong immune response. Whereas most cancer vaccine strategies attempt to boost the body's response...
BC Week In Review | May 17, 2010
Clinical News

GVAX vaccine for prostate cancer: Development restarted

BioSante restarted development of GVAX immunotherapy to treat prostate cancer and expects to begin a Phase II trial in 4Q10. The company said it is taking steps to lift the clinical hold on the program,...
Items per page:
1 - 10 of 514
BioCentury | Apr 4, 2020
Finance

Megarounds for Chinese biopharmas Legend, RemeGen to support late-stage push

A pair of Chinese biotechs raised rounds topping $100 million this week, with Legend’s fund-raise coming ahead of a planned U.S. IPO and regulatory submissions for its lead CAR T targeting BCMA, and cancer and...
BioCentury | Jun 18, 2012
Product Development

Immune springboard

A spate of Phase III data events over the next two years will give a readout on how correctly the lessons learned five years ago about cancer immunotherapies targeting T cell responses have been put...
BC Week In Review | Dec 19, 2011
Company News

Ritter management update

Ritter Pharmaceuticals Inc. , Los Angeles. Calif.   Business: Gastrointestinal   Hired: Robert Tidwell as CBO, formerly SVP of corporate development at Cell Genesys Inc. , which merged with BioSante Pharmaceuticals Inc.  ...
BC Week In Review | Nov 7, 2011
Company News

Pathwork Diagnostics management update

Pathwork Diagnostics Inc. , Redwood City, Calif.   Business: Diagnostic   Hired: Sharon Tetlow as CFO, formerly SVP and CFO of Cell Genesys Inc. , which merged with BioSante Pharmaceuticals Inc.  ...
BC Week In Review | Jun 13, 2011
Clinical News

GVAX Prostate cancer vaccine: Development restarted

BioSante said FDA lifted a clinical hold on the GVAX Prostate cancer vaccine to treat prostate cancer after additional data analyses addressed side effect concerns. BioSante is planning to begin a Phase II trial of...
BC Extra | Jun 7, 2011
Clinical News

FDA lifts hold on BioSante vaccine

FDA lifted a clinical hold on GVAX Prostate Cancer vaccine from BioSante Pharmaceuticals Inc. (NASDAQ:BPAX). The company said the hold was lifted after additional data analyses addressed side-effect concerns. BioSante is planning to begin a...
BioCentury | May 23, 2011
Strategy

Takeda's global boost

Acquiring Nycomed will transform Takeda Pharmaceutical Co. Ltd. into a complete global pharma company by combining geographically complementary marketing operations. But the Japanese pharma will need more acquisitions to get its market cap back to...
BC Week In Review | Nov 22, 2010
Company News

BioSante, Cold Genesys deal

Cold Genesys received exclusive, worldwide rights to develop and commercialize BioSante's oncolytic virus technology, including CG0070 . BioSante received a 19.9% ownership of Cold Genesys, a $95,000 upfront payment and is eligible to receive milestones and...
BC Innovations | May 27, 2010
Targets & Mechanisms

Coaxing cancer to defect

The immune system has a hard time attacking tumors because malignant cells do not express potent antigens that could elicit a strong immune response. Whereas most cancer vaccine strategies attempt to boost the body's response...
BC Week In Review | May 17, 2010
Clinical News

GVAX vaccine for prostate cancer: Development restarted

BioSante restarted development of GVAX immunotherapy to treat prostate cancer and expects to begin a Phase II trial in 4Q10. The company said it is taking steps to lift the clinical hold on the program,...
Items per page:
1 - 10 of 514